newsfilter
← Latest News
GlobeNewswire·

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1